• SHARE

The lead researcher in the coronavirus trial for flu drug Avigan says it’s too early to make a call on whether it works and shrugged off negative reports about the interim results, saying patients are still being enrolled.

The final results of the trial for the antiviral, made and sold by Fujifilm Holdings Corp., are expected around July, Dr. Yohei Doi said in an interview. Doi is leading the testing at Fujita Health University.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)